Elisabeth Gjefsen

  • PhD student; MD
  • +47 924 90 884

Background: 
Elisabeth Gjefsen has a medical doctor degree from University of Oslo in 2007.  She has been working at the neurologic department at Oslo University Hospital since 2011, and is Consultant of Neurology 

Research Project:
Elisabeth Gjefsen started the project denoted «BacktoBasic» in 2018, a randomized double blind placebo-controlled mutisenter trial where the overall concept is to assess whether a TNF-alfa inhibitor is an effective treatment in patients with chronic LBP with concomitant Modic Changes. 

Main supervisor:  Professor John-Anker Zwart, FORMI, Nevroklinikken, OUS

Co-supervisors: Kjersti Storheim, FORMI, Nevroklinikken, OUS and MD, PhD Guro Løvik Goll, Diakonhjemmet hospital,

 

Publications 2022

Vigeland MD, Flåm ST, Vigeland MD, Espeland A, Kristoffersen PM, Vetti N, Wigemyr M, Bråten LCH, Gjefsen E, Schistad EI, Haugen AJ, Froholdt A, Skouen JS, Zwart JA, Storheim K, Pedersen LM, Lie BA, AIM Study Group (2022)
Correlation between gene expression and MRI STIR signals in patients with chronic low back pain and Modic changes indicates immune involvement
Sci Rep, 12 (1), 215
DOI 10.1038/s41598-021-04189-5, PubMed 34997115

Publications 2021

Gjefsen E, Gervin K, Goll G, Bråten LCH, Wigemyr M, Aass HCD, Vigeland MD, Schistad E, Pedersen LM, Pripp AH, Storheim K, Selmer KK, Zwart JA (2021)
Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes
RMD Open, 7 (2)
DOI 10.1136/rmdopen-2021-001726, PubMed 34344830

Publications 2020

Gjefsen E, Bråten LCH, Goll GL, Wigemyr M, Bolstad N, Valberg M, Schistad EI, Marchand GH, Granviken F, Selmer KK, Froholdt A, Haugen AJ, Dagestad MH, Vetti N, Bakland G, Lie BA, Haavardsholm EA, Nilsen AT, Holmgard TE, Kadar TI, Kvien T, Skouen JS, Grøvle L, Brox JI, Espeland A et al. (2020)
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
BMC Musculoskelet Disord, 21 (1), 698
DOI 10.1186/s12891-020-03720-5, PubMed 33087100

Page visits: 2037